Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Hospital Acquired Infections Therapeutics Market

Hospital Acquired Infections Therapeutics Market Trends

  • Report ID: GMI11913
  • Published Date: Oct 2024
  • Report Format: PDF

Hospital Acquired Infections Therapeutics Market Trends

The first trend is the increasing use of rapid diagnostic tests and molecular diagnostics, which enable the swift identification of pathogens, allowing for more targeted and effective treatments. Another trend is the growing focus on antibiotic stewardship programs to manage and optimize the use of antibiotics, thereby reducing the incidence of antibiotic-resistant infections.
 

  • There is a growing focus on developing novel antimicrobial agents, such as bacteriophages and monoclonal antibodies, to combat the rising threat of multi-drug-resistant organisms. Additionally, the integration of artificial intelligence and machine learning into infection control is gaining momentum, offering predictive analytics to anticipate outbreaks and optimize treatment protocols.
     
  • Emphasis on infection prevention is also increasing, with advancements in sterilization techniques and the use of enhanced protective barriers in healthcare settings playing a critical role in reducing healthcare-associated infections (HAIs). Moreover, the expansion of telemedicine and remote monitoring technologies is improving HAI management by providing timely and efficient care, particularly in outpatient settings.
Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global market size for hospital-acquired infections therapeutics was valued at approximately USD 12.6 billion in 2023 and is expected to reach around USD 16.4 billion by 2032, driven by a CAGR of 3.2% from 2024 to 2032.

Antibacterial drugs accounted for the highest revenue of USD 9.2 billion in 2023, driven by the increasing prevalence of antibiotic-resistant bacteria in healthcare settings.

North America market generated USD 4.7 billion in 2023, driven by its high incidence of HAIs and a well-established healthcare infrastructure.

Major players in the industry include Abbott, AbbVie, Allergan Plc, Eugia Pharma, Bayer, DAIICHI SANKYO COMPANY, F. Hoffmann-La Roche, Glenmark Pharmaceuticals, GSK, and Hikma Pharmaceuticals.

Hospital Acquired Infections Therapeutics Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 15
  • Tables & Figures: 109
  • Countries covered: 19
  • Pages: 130
 Download Free Sample